TY - JOUR
T1 - Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension
AU - Kane, Garvan C.
AU - Maradit-Kremers, Hilal
AU - Slusser, Josh P.
AU - Scott, Chris G.
AU - Frantz, Robert P.
AU - McGoon, Michael D.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Frantz has received research and education grants from United Therapeutics, Actelion, Pfizer, and Gilead. None of these funds resulted in personal financial gain. Dr McGoon has received research funding from Medtronic and Gilead. He has served on advisory, steering, and/or end point/DSMB committees for Actelion, Gilead, LungRx, and Medtronic. He has received honoraria for speaking at conferences supported by Actelion and Gilead. Drs Kane and Maradit-Kremers and Messrs Slusser and Scott have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Background: Current management guidelines for pulmonary arterial hypertension (PAH) recommend a treatment choice based primarily on World Health Organization (WHO) functional class. This study was designed to assess how the incorporation of readily obtained clinical and test-based information may significantly improve the prediction of outcomes over functional class alone. Methods: Clinical and hemodynamic variables were assessed in 484 consecutive patients presenting with WHO group 1 PAH. The primary outcome measure was time to all-cause mortality over 5 years from the index presentation (data available in all). Follow-up was censored at the time of lung or heart/lung transplant in 21 patients or at 5 years. Predictors of mortality were assessed sequentially using Cox models, with the step-wise incorporation of clinical variables, echocardiographic, and catheterization findings. Results were further compared with the REVEAL (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) prediction score. Results: Overall median survival was 237 weeks (95% CI, 196-266), corresponding to 1-year, 3-year, and 5-year survival rates of 81.1% (77.0, 84.7), 61.1% (56.5, 65.3), and 47.9% (43.2, 52.4), respectively. The prediction of mortality was improved incrementally by incorporating clinical and echocardiographic measures with a concordance index (c-index) of 0.84 compared with that of 0.60 with functional class alone. The REVEAL prediction score was validated independently in this cohort to predict both 1-year and 5-year mortality. It had a prediction c-index of 0.71. Conclusions: The integration of routine PAH clinical (predominantly noninvasive) parameters predicts long-term outcome better than functional class and, hence, should be incorporated into medical management decisions.
AB - Background: Current management guidelines for pulmonary arterial hypertension (PAH) recommend a treatment choice based primarily on World Health Organization (WHO) functional class. This study was designed to assess how the incorporation of readily obtained clinical and test-based information may significantly improve the prediction of outcomes over functional class alone. Methods: Clinical and hemodynamic variables were assessed in 484 consecutive patients presenting with WHO group 1 PAH. The primary outcome measure was time to all-cause mortality over 5 years from the index presentation (data available in all). Follow-up was censored at the time of lung or heart/lung transplant in 21 patients or at 5 years. Predictors of mortality were assessed sequentially using Cox models, with the step-wise incorporation of clinical variables, echocardiographic, and catheterization findings. Results were further compared with the REVEAL (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) prediction score. Results: Overall median survival was 237 weeks (95% CI, 196-266), corresponding to 1-year, 3-year, and 5-year survival rates of 81.1% (77.0, 84.7), 61.1% (56.5, 65.3), and 47.9% (43.2, 52.4), respectively. The prediction of mortality was improved incrementally by incorporating clinical and echocardiographic measures with a concordance index (c-index) of 0.84 compared with that of 0.60 with functional class alone. The REVEAL prediction score was validated independently in this cohort to predict both 1-year and 5-year mortality. It had a prediction c-index of 0.71. Conclusions: The integration of routine PAH clinical (predominantly noninvasive) parameters predicts long-term outcome better than functional class and, hence, should be incorporated into medical management decisions.
UR - http://www.scopus.com/inward/record.url?scp=79958717109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958717109&partnerID=8YFLogxK
U2 - 10.1378/chest.10-1293
DO - 10.1378/chest.10-1293
M3 - Article
C2 - 21071530
AN - SCOPUS:79958717109
SN - 0012-3692
VL - 139
SP - 1285
EP - 1293
JO - Chest
JF - Chest
IS - 6
ER -